RT Journal Article
SR Electronic
T1 Nationwide Seroprevalence of SARS-CoV-2 in Saudi Arabia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.28.21250598
DO 10.1101/2021.01.28.21250598
A1 Alharbi, Naif Khalaf
A1 Alghnam, Suliman
A1 Algaissi, Abdullah
A1 Albalawi, Hind
A1 Alenazi, Mohammed W.
A1 Albargawi, Areeb M.
A1 Alharbi, Abdullah G.
A1 Alhazmi, Abdulaziz
A1 Qarni, Ali Al
A1 Alfarhan, Ali
A1 Zowawi, Hossam M.
A1 Alhatmi, Hind
A1 Alghamdi, Jahad
A1 Alroqi, Fayhan
A1 Arabi, Yaseen M.
A1 Hashem, Anwar M.
A1 Bosaeed, Mohammed
A1 Aldibasi, Omar
YR 2021
UL http://medrxiv.org/content/early/2021/01/31/2021.01.28.21250598.abstract
AB Background Estimated seroprevalence of Coronavirus Infectious Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is a critical evidence for a better evaluation of the virus spread and monitoring the progress of the COVID-19 pandemic in a population. In the Kingdom of Saudi Arabia (KSA), SARS-CoV-2 seroprevalence has been reported in specific regions, but an extensive nationwide study has not been reported. Here, we report a nationwide study to determine the prevalence of SARS-CoV-2 in the population of KSA during the pandemic, using serum samples from healthy blood donors, non-COVID patients and healthcare workers (HCWs) in six different regions of the kingdom, with addition samples from COVID-19 patients.Methods A total of 11703 serum samples were collected from different regions of the KSA including; 5395 samples from residual healthy blood donors (D); 5877 samples from non-COVID patients collected through residual sera at clinical biochemistry labs from non-COVID patients (P); and 400 samples from consented HCWs. To determine the seroprevalence of SARS-CoV-2, all serum samples, in addition to positive control sera from RT-PCR confirmed COVID-19 patients, were subjected to in-house ELISA with a sample pooling strategy, which was further validated by testing individual samples that make up some of the pools, with a statistical estimation method to report seroprevalence estimatesResults Overall (combining D and P groups) seroprevalence estimate was around 11% in Saudi Arabia; and was 5.1% (Riyadh), 1.5% (Jazan), 18.4% (Qassim), 20.8% (Hail), 14.7% (ER; Alahsa), and 18.8% in Makkah. Makkah samples were only D group and had a rate of 24.4% and 12.8% in the cities of Makkah and Jeddah, respectively. The seroprevalence in Saudi Arabia across the sampled areas would be 12 times the COVID-19 infection rate. Among HCWs, 7.5% (4.95-10.16 CI 95%) had reactive antibodies to SARS-CoV-2 without reporting any previously confirmed infection. This was higher in HCWs with hypertension. The study also presents the demographics and prevalence of co-morbidities in HCWs and subset of non-COVID-19 population.Conclusion Our study estimates the overall national serological prevalence of COVID-19 in Saudi Arabia to be 11%, with an apparent disparity between regions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by KAIMRC, Grant: RC20/180; PI: Naif K. Alharbi.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the IRB in KAIMRC (Ministry of National Guard Health Affairs) for project number RC20-180. Residual samples from blood banks and clinical laboratories were obtained after an IRB approval. COVID-19 patients and HCWs signed informed consents to give blood samples.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are analysed and reported in the manuscript. Raw data are available by requesting it from the authors.